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GENERAL THORACIC SURGERY 
RESECTION AND ADJUVANT 
IMMUNOTHERAPY FOR 
MELANOMA METASTATIC TO 
THE LUNG AND THORAX 
Although melanoma that metastasizes to distant sites is generally associated 
with a median survival of only 6 to 8 months, certain metastatic sites including 
the lung may carry a better prognosis than others. Surgical therapy for 
pulmonary metastases remains controversial because of the variable survival 
rates reported for previous small series. To determine the prognosis and 
optimal management of patients with melanoma with pulmonary metastases, 
we reviewed our 22-year melanoma database of over 6100 patients. Of 984 
patients with metastatic melanoma involving the lung or thorax, 106 under- 
went resection by posterior lateral thoracotomy or median sternotomy. There 
were no operative deaths, and the median follow-up eriod for surgical patients 
was 55 months. The remaining 878 patients were treated without operation 
with immunotherapy, chemotherapy, radiation therapy, or a combination. In 
both treatment groups the male/female ratio was approximately 2:1. The 
primary lesion's Clark level of invasion and Breslow thickness and the 
patient's age at diagnosis of metastatic disease were not significantly different 
between the two groups. The 1-year, 3-year, and 5-year survival rates for 
surgical patients were 77%, 37%, and 27%, respectively, compared with 32%, 
7%, and 3% for nonsurgical patients; these differences were highly significant 
(p = 0.0001). The highest 5-year survival rate (39%) occurred in those patients 
with a single metastatic lesion. Sixty-three percent of the surgical patients 
received some form of immunotherapy, compared with 34% of the nonsurgical 
patients. Multivariate analysis howed that resection and immunotherapy with 
a melanoma cell vaccine were both independent predictors of survival (p < 
i 
0.0001). These results indicate that the prognosis associated with metastatic 
melanoma may be less dismal than previously thought when distant metasta- 
ses involve thoracic sites. We believe that surgical resection is the treatment of
choice for patients with melanoma with pulmonary metastases; when com- 
bined with immunotherapy, this regimen offers the best chance for long-term 
survival. (J THORAC CARDIOVASC SURG 1995;110:119-29) 
Lorraine Tafra, MD (by invitation), Paul S. Dale, MD (by invitation), 
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p atients with melanoma metastatic to distant sites 
usually have a poor prognosis. It is commonly 
assumed that melanoma follows the pattern of other 
carcinomas uch as breast cancer, in which signs of 
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distant spread usually indicate disseminated disease 
that requires systemic therapy rather than local 
treatment. However, a number of reports have 
shown that metastatic melanoma can be unpredict- 
able and that some patients can survive for extended 
periods after resection of distant metastases. >6
These findings point toward reevaluation of the role 
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of surgical resection in the management of patients 
with melanoma with advanced isease. 
Thoracotomy for resection of metastatic disease is 
credited to Sedilott in 1885, 7but the procedure was 
first performed with curative intent by Barney and 
Churchill 8 in 1939. In the early 1940s, Alexander 
and Haight 9 described their results in 24 patients 
undergoing surgical resection of pulmonary metas- 
tases; their short-term survival data generated en- 
thusiasm for surgical intervention i  these patients. 
9 However subsequent s udies reported that although 
thoracotomy improved the survival of some patients 
with carcinomas and sarcomas, patients with mela- 
noma fared the worst. 10-17 More recent studies 
examining the role of thoracotomy specifically in 
patients with metastatic melanoma report variable 
survival ratesJ' 2, 10, 15, 16,18-22 Like preceding stud- 
ies, however, these studies have relatively few pa- 
tients. The Duke experience reported by Harpole 
and colleagues 22 is the largest study to date, and its 
overall 5-year survival rate of 20% provides ome 
optimism for the surgical management of patients 
with melanoma metastatic to the lung. 
In 1988 we reported a25% 5-year survival rate for 
47 patients undergoing resection of melanoma met- 
astatic to the lung. 1 This rate, the highest yet 
reported in this group of patients with melanoma, 
reflected strict selection criteria: tumor doubling 
time (TDT) more than 40 days, limited number of 
pulmonary metastatic sites, documented absence of 
extrapulmonary intrathoracic disease, and long dis- 
ease-free interval. Because survival was excellent, 
we subsequently relaxed these selection criteria to 
study the xesults for a less rigidly selected operative 
group. We undertook the present study to  deter- 
mine the survival rate associated with less stringent 
selection criteria and to identify selection criteria 
associated with improved survival after aggressive 
surgical resection of pulmonary and thoracic metas- 
tases. Thus our first objective was to define more 
clearly the role of thoracotomy in the treatment of 
patients with melanoma with pulmonary metastases. 
In 1985 we began clinical trials of our new poly- 
valent melanoma cell vaccine (MCV), 23 a highly 
immunogenic preparation consisting of irradiated 
cells from three human melanoma lines. The success 
of MCV in a phase II trial of patients with mela- 
noma wi threg iona l  and distant metastases 
prompted its routine application as a postoperative 
adjuvant herapy. Thus our second objective was to 
determine the impact of MCV adjuvant immuno- 
therapy on the long-term prognosis of patients with 
melanoma undergoing surgical resection of pulmo- 
nary metastases. 
Patients and methods 
We reviewed the clinical records of 6129 patients with 
melanoma treated by the staff of the John Wayne Cancer 
Institute (JWCI) during the 22-year period from 1971 
through 1993. These records were coded and entered into 
JWCI's computerized database developed to follow up 
patients with melanoma. 
Of 2167 patients with melanoma with distant metasta- 
ses, 984 patients had pulmonary involvement; 106 of 984 
(11%) underwent surgical resection of pulmonary metas- 
tases, and 117 operations were performed. The median 
follow-up period from diagnosis of the primary disease 
was 55 months for surgically treated patients and 33 
months for nonsurgically treated patients. The period of 
follow-up observation after development of pulmonary 
metastases was shorter: 17 and 7 months for nonsurviving 
surgical and nonsurgical patients, respectively, and 27 and 
11 months for surviving surgical and nonsurgical patients, 
respectively. Mean age at diagnosis of pulmonary metas- 
tases was 52 and 51 years for surgical and nonsurgical 
patients, respectively. There were 66 male patients (62%) 
and 40 female patients (38%) in the surgical group, and 
584 male patients (67%) and 294 female patients (33%) in 
the nonsurgical group. 
The characteristics of the primary tumor (location, 
histologic type, thickness, level of invasion) and the type 
of operative/nonoperative treatment for metastatic dis- 
ease were recorded in detail for each case. Thoracotomies 
were classified as wedge resection, lobectomy, pneumo- 
nectomy, or other (i.e., thoracoscopic resection, medias- 
tinal dissection/resection, andresection of an unspecified 
amount of pulmonary or mediastinal tissue). The presence 
of extrapulmonary intrathoracic disease was determined, 
as well as the number of pulmonary lesions and whether 
all sites of metastatic disease were resected. TDT was 
calculated before operation, according to a previously 
described technique, z4or determined retrospectively b
review of radiographs and tumor measurements. 
Many of these patients participated in adjuvant immu- 
notherapy protocols, receiving nonspecific immunother- 
apy with bacille Calmette-Guerin vaccine, immunization 
with a tumor cell vaccine, or active specific immunother- 
new polyvalent MCV. Administration of apy with the 25 
these immunotherapies is described elsewhere. 26" 27 We 
examined the impact of postoperative adjuvant immuno- 
therapy on the survival of patients with melanoma. 
Statistical analyses. Survival time was defined as the 
months a patient remained alive after documented lung 
metastases. Estimated survival rates were obtained with 
the nonparametric Kaplan-Meier method. The log-rank 
test was used to determine the difference insurvival curves 
among subgroups of patients, and statistical significance 
was defined as an alpha level of 0.05. Multivariate analysis 
was modeled under the Cox proportional hazards tech- 
nique. Any variable not statistically significant accord- 
ing to univariate analysis was excluded from the multivar- 
iate model. The statistical package of SAS procedures 
LIFETEST and PHREG software (SAS Institute, Inc., Cary, 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 110, Number 1 
Tafra et al. 121 
Table I. Cumulative risk of developing pulmonary 
metastases 
Total database 
population Subgroup* 
No. of database patients 
Total 
With lung metastases 
All other 
Cumulative risk 
3 years 
5 years 
10 years 
15 years 
20 years 
6129 3779 
984 351 
5145 3428 
0.10 
0.15 0.10 
0.19 0.12 
0.23 0.13 
0.27 0.13 
~This ubgroup included all patients treated at JWCI within 4 months Of 
primary diagnosis: it excluded patients presenting to JWCI staff with 
metastatic disease and those with unknown primary disease. 
N.C. ) was used for univariate and multivariate analyses. The 
standard ~ statistic compared prognostic variables insurgi- 
cal and nonsurgical groups, and a standard t test compared 
disease-free survival in the treatment groups. (Disease-free 
survival was defined as the disease-free interval between 
treatment ofprimary lesion/nodal metastases to diagnosis of 
pulmonary metastases.) SAS procedures FREQ and TTEST 
software (SAS Institute) were used to calculate the X 2 and 
t test statistics, respectively. 
Results 
Risk of pulmonary metastases. Table I shows the 
3-, 5-, 10-, 157, and 20-year risk of  developing 
pulmonary metastases in all 6129 melanoma data- 
base patients and in a subgroup used to examine the 
natural history of melanoma metastatic to the lungs. 
This subgroup included all patients treated at JWCI 
within 4 months of diagnosis; it excluded patients 
presenting to JWCI staff with metastatic disease and 
those with unknown primary disease. Thus, the 
5-year risk of pulmonary metastases developing is 
10%; after 5 years the risk is about 13% per year. 
Cox multivariate regression analysis howed that the 
following factors increased the risk of pulmonary 
metastases (Table II): male gender, increasing thick- 
ness and invasion of the primary tumor, increasing 
age of the patient, nodular histologic status of the 
tumor, and nodal metastases. 
Analysis of the surgical group. Of the 106 surgi- 
cal patients, nine underwent multiple procedures: 
six patients had two resections and three patients 
underwent three operations. Wedge resection was 
the most common procedure (71 cases, 61%), fol- 
lowed by lobectomy (25 cases, 21%), and pneumo- 
nectomy (six cases, 5%). Fifteen other cases (13%) 
involved resection of extrapulmonary metastases in
Table II. Univariate and multivariate analyses of 
variables affecting development ofpulmonary 
metastases in subgroup* of melanoma patients 
p Value 
Univariate Multivariate 
Variable analysis analysis 
Gender 0.0234 0.0234 
Breslow thickness (mm) 0.0001 0.0001 
Patient age (yr) 0.0079 0.0164 
Clark level of invasion 02001 0.0004 
Type of melanoma 0.0001 0.0006 
Nodal metastasis 0.0001 0.000t 
*This subgroup included all patients treated at JWCI within 4 months of 
diagnosis; it excluded patients presenting to JWCI staff with metastatic 
disease and those with unknown primary disease. 
the chest wall, mediastinum, or lymph nodes and 
resection in which the exact amount of excised tissue 
was not recorded. 
The majority of patients had pulmonary involve- 
ment: 68 patients (68%) had isolated pulmonary 
metastases, and 26 (26%) had pulmonary metasta- 
ses plus nonpulmonary intrathoracic metastases. 
Only four patients had disease confined to extrapul- 
monary intrathoracic sites. The mean number of 
lung metastases was two (range 1 to >10); 56 
patients (52%) had one metastasis, 23 (22%) had 
two to three, and 28 (26%) had, more than 3. The 
most common technique of resection was posterior 
lateral thoracotomy (108 procedures); in addition, 
eight median sternotomies and one thoracoscopic 
resection were performed. 
Of the 106 patients, 65 underwent removal of all 
visible tumor; the remaining 41 had an incomplete 
or unknown amount of tumor removed uring the 
first surgical procedure. 
Surgical mortality and morbidity. Surgical mor- 
tality for the 117 procedures was zero. The most 
common postoperative complications were pulmo- 
nary edema requiring reintubation (three patients) 
and cardiac arrhythmia (three patients). Other 
problems included bleeding requiring reoperation 
(two patients) and massive tissue emphysema re- 
quiring replacement of chest tubes (one patient). 
Survival with surgical therapy. Univariate analy- 
sis identified the number of lung metastases, the 
presence of extrapulmonary metastases, and the 
TDT as significant variables affecting the prognosis 
of patients with melanoma undergoing resection of 
pulmonary metastases (Table III). Only TDT and 
the presence of extrapulmonary intrathoracic dis- 
ease were significant by multivariate analysis, with 
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Fig. 1. Survival of patients with melanoma undergoing complete versus incomplete resection of pulmo- 
nary metastases (p = 0.07). Vertical bars indicate the standard error of the mean; numbers indicate the 
number of survivors. 
Table III. Univariate and multivariate analyses of 
factors affecting survival of surgical patients 
p Value 
Univariate Multivariate 
" Variable analysis analysis 
Tumor doubling time 0.0005* 0.0020* 
(<60 vs. >60 days) 
Presence of extrapulmonary 0.014" 0.0423* 
metastases 
No. of lung metastases 0.006* 0.8969 
(1 vs. >1) 
Complete vs. incomplete 0.091 - -  
resection 
Wedge resection vs. lobec- 0.130 
tomy 
Disease-free interval 0.3150 - -  
(--<30 vs. >30 mo) 
*p < 0.05 
the number of pulmonary metastases becoming less 
important. Figs. ~ through 6 show survival curves 
according to various prognostic factors. Those pa- 
tients undergoing complete resection had a higher 
5-year and median survival than those undergoing 
incomplete resection. (Patients undergoing an Un- 
known degree of resectionwere not included.) The 
difference between their respective survival curves 
approached but did not reach significance because 
of the small number of patients undergoing incom- 
plete resection (Fig. 1). A significant survival advan- 
tage was present for patients with less than five 
pulmonary lesions (Fig. 2). In addition, the 5-year 
survival rate tended to decrease as the number of 
pulmonary metastases increased from one (39%; 
Fig. 3) to between one and four (29%). 
Preoperative TDT, available for only 26 surgical 
patients, ranged from 40 to 400 days, with a median 
of 80 days. A significant Survival advantage was asso- 
ciated with TDT greater than 60 days (p = 0.0005; Fig. 
4). Although patients undergoing lobectomy appeared 
to do better, their median survival was not statistically 
different from that of patients undergoing wedge re- 
section (28 versus 25 months, respectively; data not 
shown). Patients without extrapulmonary intrathoracic 
metastases had a significant survival advantage; their 
5-year survival rate was 30%, compared with 11% for 
other patients (Fig. 5). Moreover, their 5-year survival 
rate increased to 38% when the absence of extrapul- 
monary intrathoracic metastases was accompanied by 
the presence of only one pulmonary metastasis (Fig. 
6). There were no 5-year survivors among patients with 
multiple pulmonary metastases plus extrapulmonary 
intrathoracic metastases. 
The median survival for the nine patients under- 
going multiple procedures was 33 months. Of those 
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Fig. 2. Survival of patients with melanoma with one to four versus five or more pulmonary metastases 
(p = 0.015). VertiCal bars indicate the standard error of the mean; numbers indicate the number of survivors. 
patients with extrapulmonary intrathoracic metasta- 
ses, two died 5, and 14 months after resection, and 
two were alive at 18 and 149 months of follow-up. 
Survival of patients with pulmonary metastases. 
Univariate analysis howed that surgical treatment 
plus MCV immunotherapy, location of the primary 
on an extremity, and extended isease-free interval 
wei'e associated with improved survival. In the mul- 
tivariate analysis, only surgical treatment and MCV 
immunotherapy remained significant (Table IV). 
The median survival time and the 5-year survival 
rate for the entire group of patients with pulmonary 
metastases were 9 months and 6%, respectively. 
Kaplan-Meier survival analysis showed improved 
survival in patients treated with resection (Fig. 7). 
Median survival time and 5-year survival rate were 8 
months and 3%, respectively, for nonsurgical pa- 
tients versus 23 months and 27% for surgical pa- 
tients. This difference in survival between surgical 
and nonsurgical groups could not be explained by 
the location, hist01ogic status, thickness, or level of 
invasion of the primary melanoma (data not shown). 
These factors ,were not significantly different be- 
tween surgical and nonsurgical groups. 
However, surgical patients did have a significantly 
longer median disease-free interval (from diagnosis 
of primary or presentation with nodal metastases 
from an unknown primary, to development of pul- 
monary metastases) than did nonsurgical patients 
(33 versus 18 months, respectively; p = 0.02). Be- 
cause the disease-free interval has been shown to 
correlate with tumor growth rates as judged by TDT, 
we analyzed the subset of patients with longer 
disease-free intervals. After controlling for disease- 
free interval in both groups, the surgical patients till 
had improved survival. Fig. 8 presents survival 
curves for 48 surgical and 255 nonsurgical patients 
with equivalent disease-free intervals (>30 months). 
The median and 5-year survival statistics remained 
significantly better in patients undergoing resection 
(23 months and 35% versus 8 months and 5%, 
respectively; p = 0.0001). 
Impact of adjuvant immunotherapy with MCV. 
According to multivariate analysis, MCV immune- 
therapy was the only factor other than resection that 
was associated with improved survival (Table IV): 
63% of surgical patients received some form of 
immunotherapy, compared with only 34% of non- 
surgical patients. Median survival was longer in 
patients treated with MCV (13 months) than in 
those treated with other nonsurgical therapies (8 
months). 
Discussion 
Analysis of these data, which represent the largest 
series of surgically treated patients with melanoma 
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metastatic to the lung and thorax, showed that the 
rate ,Of 5-year Survival can be as high as 39% in 
selected patients. This is a striking contrast o the 
median survival of 8 months generally ascribed to 
patients with melanoma metastatic to distant 
s i tes .  10-13 '2s '29  The implication is that certain pa- 
tients with thoracic metastases should be considered 
for possible operative management. The fact that 
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operative mortality was zero and operative morbid- 
ity was low also offers support for surgical interven- 
tion in selected patients. 
Previous studies have reported surgical treatment 
of patients with melanoma metastatic to the lung or 
other sites, i' 14-16, 19, 20-22 but few have had enough 
patients for detailed analysis, The variables associ- 
ated with increased risk of pulmonary metastases in
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Table IV. Univariate and multivariate analyses of 
survival variables in patients with pulmonary 
metastases 
Variable 
p Value 
Univariate Multivariate 
analysis analysis 
Operation vs. no operat ion 0.0001" 0.0001" 
MCV immunotherapy vs. 0.0001" 0.0001" 
no MCV immunother- 
apy 
Breslow thickness 0.4769 - -  
Clark level of invasion 0.1639 - -  
Gender 0.3238 - -  
Site of primary 0.007* 0.282 
Disease-free interval 0.0008* 0.0967 
--<-30 vs. >30 mo 
*p < 0.05 
our multivariate analysis were similar to those re- 
ported by Harpole and colleagues. 22Our  study 
group's higher overall risk of the development of 
pulmonary metastases (Table I) reflects the fact that 
JWCI is a tertiary referral center for patients with 
melanoma. The risk for our subgroup (i.e., those 
treated at JWCI within 4 months of primary diag- 
nosis), which better represents patients with mela- 
noma, most probably approximates the true risk of 
pulmonary metastases in melanoma. 
Our study group was large enough to determine 
the best candidates for resection (i.e, patients with 
a solitary pulmonary lesion, no evidence of extrapul- 
monary intrathoracic metastases, and a TDT > 60 
days). However, patients with multiple metastases 
and no extrapulmonary intrathoracic disease can 
still have a 5-year survival rate of  19% and therefore 
should be considered for resection. 
Because of the small number of patients under- 
going incomplete resection, no statistical difference 
was seen for complete versus incomplete resection; 
however, the respective survival curves were sepa- 
rate and would doubtless become statistically differ- 
ent as the number of patients increased. TDT was 
frequently described as greater or less than 40 days, 
but its specific value was recorded for only 26 
patients. This is unfortunate because TDT is a 
valuable selection criterion for surgical candi- 
dates. 29-3~ Traditionally, patients with a TDT less 
than 40 days have not been considered for resection, 
and there were no 5-year survivors among patients 
whose TDT was less than 60 days. However, surgical 
intervention may still be considered if the patient 
has a solitary pulmonary lesion, no extrapulmonary 
intrathoracic metastases, or other favorable prog- 
nostic factors. 
Although no statistically significant difference was 
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found between treatment with lobectomy versus 
wedge resection, 5-year survival increased in those 
patients undergoing the latter procedure. This note- 
worthy trend may reflect use of lobectomy for 
patients with a single large metastatic lesion. 
No previous eries has reported survival data for 
patients with melanoma undergoing resection of 
extrapulmonary intrathoracic metastases. Although 
our study had only four such patients, three survived 
for more than 1 year. This acceptable rate of survival 
offers support for aggressive surgical managenient in 
selected patients. It has been suggested that median 
sternotomy is too aggressive for resection of bilat- 
eral metastases. However, Regal and Colleagues 31
preferred this approach in their series of 131 pa- 
tients. Of the eight patients in our study who 
underwent median sternotomy, one required reintu- 
bation because of pulmonary edema and one re- 
quired treatment of cardiac arrhythmia; however, 
both recovered well. 
In our study, administration of immunotherapy 
was associated with improved outcome. A prospec: 
tive randomized study is needed to identify patients 
most likely to benefit from this intervention. How- 
ever, both clinical studies 23 and experimental work 
with the use of animal models 32 point to improved 
survival after use of immunotherapy. Although the 
various regimens of adjuvant immunotherapy used 
during the 22-year study period complicate a com- 
parative analysis, the data indicate that MCV immu- 
notherapy improved the survival of patients with 
pulmonary metastases. 
Even though our selection criteria have been 
relaxed, these patients continue to have a much 
better survival rate than do patients with melanoma 
whose thoracic metastases are not treated surgically. 
Althougla our study is limited by the selection bias of 
any retrospective analysis, we believe that if thor- 
ough evaluation fails to show sites of extrathoracic 
metastasis, if the patient is in overall good health, 
and all tumor can be resected uring the surgical 
procedure, then thoracotomy and resection of me- 
tastases, followed by immunotherapy with our new 
MCV, offers the best chance for long-term survival. 
In summary, these data offer support for a more 
optimistic and aggressive approach to patients with 
malignant melanoma that metastasizes to the thorax 
and lungs. We conclude that the treatment of choice 
for this stage of melanoma issurgical intervention plus 
immunotherapy in selected patients. 
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Discussion 
Dr. Joel D. Cooper (St. Louis, Mo.)~ Your paper actually 
casts a somewhat different point of view than what I have 
always had. I have always been rather discouraged when 
melanoma has shown up in the lung compared with other 
metastatic tumors. I congratulate yon on the series. 
I have one question. I believe you showed us that the 
difference in the interval between th e primary tumor and 
the treatment was significantly different for those having 
and those not having surgical treatment; and, having 
shown the importance of tumor doubling time, how much 
do you think this factor contributes to your ultimate 
conclusion? 
Dr. Tafra. Just to clarify your question, how much does 
the interval affect.. .  ? 
Dr. Cooper. The selection of patients. Your conclusion 
was that surgery plays a role, and yet when you analyzed 
the results of the surgical versus the nonsurgical group of 
patients, if I understand it correctly, there was a much 
greater disease-free interval from the time of primary 
disease to the time of treatment in those undergoing 
surgical treatment than in those who did not have surgical 
treatment. In other words, were they preselected? 
Dr. Tafra. Certainly there was a selection bias. Without 
a prospective, randomized comparison of patients having 
a similar number of lesions and a similar tumor burden, 
we cannot prove that surgically treated patients fare better 
than those treated without operation. However, there is 
some evidence showing that surgical patients have im- 
proved survival. First, since we relaxed our selection 
criteria for operation 5 years ago, the tumor burden of our 
surgical patients has increased, yet their survival rate has 
remained the same. Second, although disease-free interval 
was significantly different between surgical and nonsurgi- 
cal groups, this significance was not maintained in the 
multivariate analysis of patients with pulmonary metastases. 
Dr. David J. Sugarhaker (Boston, Mass.). I would just 
like to preface my remark s by saying that I think most of 
us approach patients with metastatic melanoma to the 
lung with a certain amount of trepidation, knowing that in 
a vast majority, after surgical resection, the other shoe will 
drop and the patient will turn up with an unresectable 
brain metastasis or something similar to that. 
You showed us a 42% survival in patients having one to 
four lesions. Can you give us a little further breakdown as 
to how many of those patients had only one lesion and 
how many actually had anywhere from two to four, 
because I think most of the series suggest that when you 
get more than one--when you get to two, three, and four 
lesions--survival really begins to fall off. 
Dr. Tafra. The 5-year survival of these patients is 
related to the number and location of metastases. The 
majority of our patients had only one lesion and a 5-year 
survival rate of 39%, whereas patients with 1 to 4 lesions 
had a 5-year survival rate of 29%. The survival decreases 
further with an increasing number of lesions, and we had 
no 5-year survivors with 5 or more metastatic lesions. In 
general, we do not offer surgical treatment to patients with 
more than five metastatic lesions. 
Undetected metastatic disease is a serious concern in 
these patients and we therefore perform a thorough 
metastatic workup that includes positron emission tomo- 
graphic scans, which are sensitive for detecting metastatic 
disease. If this workup shows metastatic loci in extrattio- 
racic sites, then the patient is generally not considered a 
candidate for resection. Other relative contraindications 
for surgical intervention include a rapid TDT and the 
presence o f  extrapulmonary intrathoracic disease. 
Dr. George B. Haasler (Milwaukee, Wis.). My question 
is really a corollary to Dr. Cooper's comment. Because the 
disease-free interval in the surgical patients was so much 
greater than that in the nonsurgical patients, I wondered 
whether you looked at those patients in the surgicM group 
who had shorter disease-free intervals and compared 
them with the group in the medical, nonsurgical group 
that perhaps had disease-free intervals that were on the 
longer end of that spectrum to try and get a little closer 
comparison of the surgical versus nonsurgical patients. 
Dr. Tafra. We initially did not examine the survival of 
surgically versus nonsurgically treated patients grouped 
according to disease-free interval. Our data do suggest a
close correlation between postoperative disease-free in- 
terval and TDT; however, this analysis was limited be- 
cause TDT was usually recorded as above/below a cut-off 
value rather than as a specific number. In our multivariate 
analysis, disease-free interval did not influence survival, 
and I therefore would suspect that surgically treated 
patients survived longer than nonsurgically treated pa- 
tients having a similar disease-free interval. In fact, we 
subsequently compared surgically treated patients whose 
disease-free interval exceeded 30 days with nonsurgical 
patients having the same disease-free interval: the surgical 
group continued to have improved survival. 
